Pochettino A, Kotloff R M, Rosengard B R, Arcasoy S M, Blumenthal N P, Kaiser L R, Bavaria J E
Division of Cardiothoracic Surgery and Pulmonary, University of Pennsylvania Medical Center, Philadelphia, USA.
Ann Thorac Surg. 2000 Dec;70(6):1813-8; discussion 1818-9. doi: 10.1016/s0003-4975(00)01970-6.
There is controversy regarding the transplant procedure of choice in chronic obstructive pulmonary disease. We reviewed our intermediate-term outcomes with single lung transplantation (SLT) versus bilateral lung transplantation (BLT).
We retrospectively reviewed 130 patients with chronic obstructive pulmonary disease: 84 underwent SLT, 46 BLT. The mean age was 51.1 +/- 1.2 years for those who underwent BLT and 56.2 +/- 0.7 years for those who underwent SLT (p < 0.0001). Male patients represented 65% of the BLT group and 46% of the SLT group (p = 0.04). Spirometry and 6-minute walk tests were obtained preoperatively and at 3- to 6-month intervals. Posttransplant survival and survival from time of onset of bronchiolitis obliterans syndrome were calculated by Kaplan-Meier method. The mean follow-up was 32.4 months.
The 90-day mortality rate was 13.0% For BLT and 15.5% for SLT (p = 0.71). Actuarial survival rates at 1, 3, and 5 years were 82.6%, 74.6%, and 61.9% for BLT and 72.2%, 63.4%, and 57.4% for SLT; the favorable survival trend with BLT did not achieve statistical significance. There were no differences in preoperative spirometry or 6-minute walk tests. The improvements in forced expiratory volume in one second, forced vital capacity (FVC), and 6 MWT were significantly greater following BLT. The incidence of bronchiolitis obliterans syndrome was 22.4% in SLT and 22.2% in BLT; survival following onset of bronchiolitis obliterans syndrome was similar.
For patients with chronic obstructive pulmonary disease, BLT is associated with superior lung function, exercise tolerance, and a trend toward enhanced survival. Younger candidates may be best suited for BLT. Given the limited donor lungs, SLT remains the preferred alternative for all other patients.
在慢性阻塞性肺疾病的移植手术选择方面存在争议。我们回顾了单肺移植(SLT)与双肺移植(BLT)的中期结果。
我们回顾性分析了130例慢性阻塞性肺疾病患者:84例行SLT,46例行BLT。接受BLT患者的平均年龄为51.1±1.2岁,接受SLT患者的平均年龄为56.2±0.7岁(p<0.0001)。男性患者在BLT组中占65%,在SLT组中占46%(p = 0.04)。术前及术后每隔3至6个月进行一次肺活量测定和6分钟步行试验。采用Kaplan-Meier法计算移植后生存率和闭塞性细支气管炎综合征发病后的生存率。平均随访时间为32.4个月。
BLT的90天死亡率为13.0%,SLT为15.5%(p = 0.71)。BLT在1年、3年和5年的精算生存率分别为82.6%、74.6%和61.9%,SLT分别为72.2%、63.4%和57.4%;BLT的良好生存趋势未达到统计学意义。术前肺活量测定或6分钟步行试验无差异。BLT后一秒用力呼气量、用力肺活量(FVC)和6分钟步行试验的改善明显更大。SLT组闭塞性细支气管炎综合征的发生率为22.4%,BLT组为22.2%;闭塞性细支气管炎综合征发病后的生存率相似。
对于慢性阻塞性肺疾病患者,BLT与更好的肺功能、运动耐量及生存改善趋势相关。较年轻的候选者可能最适合BLT。鉴于供肺有限,SLT仍是所有其他患者的首选替代方案。